Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality

Detalles Bibliográficos
Autores principales: Feher, Michael, Joy, Mark, Munro, Neil, Hinton, William, Williams, John, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590506/
https://www.ncbi.nlm.nih.gov/pubmed/34802683
http://dx.doi.org/10.1016/j.atherosclerosis.2021.11.012
_version_ 1784598983926087680
author Feher, Michael
Joy, Mark
Munro, Neil
Hinton, William
Williams, John
de Lusignan, Simon
author_facet Feher, Michael
Joy, Mark
Munro, Neil
Hinton, William
Williams, John
de Lusignan, Simon
author_sort Feher, Michael
collection PubMed
description
format Online
Article
Text
id pubmed-8590506
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-85905062021-11-15 Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality Feher, Michael Joy, Mark Munro, Neil Hinton, William Williams, John de Lusignan, Simon Atherosclerosis Correspondence Elsevier B.V. 2021-12 2021-11-13 /pmc/articles/PMC8590506/ /pubmed/34802683 http://dx.doi.org/10.1016/j.atherosclerosis.2021.11.012 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Feher, Michael
Joy, Mark
Munro, Neil
Hinton, William
Williams, John
de Lusignan, Simon
Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
title Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
title_full Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
title_fullStr Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
title_full_unstemmed Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
title_short Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality
title_sort fenofibrate as a covid-19 modifying drug: laboratory success versus real-world reality
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590506/
https://www.ncbi.nlm.nih.gov/pubmed/34802683
http://dx.doi.org/10.1016/j.atherosclerosis.2021.11.012
work_keys_str_mv AT fehermichael fenofibrateasacovid19modifyingdruglaboratorysuccessversusrealworldreality
AT joymark fenofibrateasacovid19modifyingdruglaboratorysuccessversusrealworldreality
AT munroneil fenofibrateasacovid19modifyingdruglaboratorysuccessversusrealworldreality
AT hintonwilliam fenofibrateasacovid19modifyingdruglaboratorysuccessversusrealworldreality
AT williamsjohn fenofibrateasacovid19modifyingdruglaboratorysuccessversusrealworldreality
AT delusignansimon fenofibrateasacovid19modifyingdruglaboratorysuccessversusrealworldreality

Ejemplares similares